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Abstract
Background: The ubiquitin-proteasome system is the primary proteolysis machine for controlling protein stability of the
majority of regulatory proteins including those that are critical for cancer development. The forkhead box transcription
factor FOXO3 plays a key role in regulating tumor suppression; however, the control of FOXO3 protein stability remains to
be established. It is crucial to elucidate the molecular mechanisms underlying the ubiquitin-mediated degradation of
FOXO3 tumor suppressor.
Methodology and Principal Findings: Here we show that bTrCP1 oncogenic ubiquitin E3-ligase interacts with FOXO3 and
induces its ubiquitin-dependent degradation in an IkB kinase-b phosphorylation dependent manner. Silencing bTrCP1
augments FOXO3 protein level, resulting in promoting cellular apoptosis in cancer cells. In animal models, increasing FOXO3
protein level by silencing bTrCP1 suppresses tumorigenesis, whereas decreasing FOXO3 by over-expressing bTrCP1
promotes tumorigenesis and tumor growth in vivo.
Conclusions/Significance: This is a unique demonstration that the bTrCP1-mediated FOXO3 degradation plays a crucial role
in tumorigenesis. These findings significantly contribute to understanding of the control of FOXO3 stability in cancer cells
and may provide opportunities for developing innovative anticancer therapeutic modalities.
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Introduction
FOXO3 (or FOXO3a) is a member of the forkhead box class O
(FOXO) transcription factors which have been shown to play
critical roles in modulating a number of cellular processes, such as
metabolism, differentiation, and transformation in animal cells
[1–7]. Strikingly, recent gene knockouts reveal FOXOs’ vital
functions in tumor suppression [8,9] and the maintenance of the
hematopoietic stem cell pool [8,10,11]. Activation of FOXO
factors was shown to regulate the expression of specific target
genes that modulate the cell metabolic state, oxidative stress, aging
[1,2,12], and those that control cell cycle progression including
cyclin B and Polo-like kinase [13,14] and DNA damage [15–17].
While multiple mechanisms have been shown to regulate
FOXO3 activity, there is a consensus that nuclear translocation of
FOXO3 protein is critical to its regulation and function. Upon
stimulation with growth factors, tyrosine kinase receptors trigger
phosphoinositide 3-kinase (PI3K) to activate serine/threonine
kinases such as the Akt family of protein kinases that phosphor-
ylate FOXO3 protein. Phosphorylated FOXO3 protein then
binds to 14-3-3 proteins that facilitate the translocation of FOXO3
from the nucleus into the cytoplasm [1,2,18]. This nuclear
exclusion and translocation of FOXO3 into the cytoplasm inhibits
FOXO3-dependent transcription. In the absence of stimulation
from survival signals, Akt is inactivated in quiescent cells, which
results in retention of FOXO3 protein in the nucleus and
activation of FOXO3-dependent transcription. Other kinases
such as IkB kinase (IKK)-b and JNK are also important in
regulating nuclear exclusion of FOXO3, resulting in inhibition of
FOXO3 function. Loss of function of FOXO3 through phos-
phorylation has been linked to tumorigenesis and poor patient
survival in cancer, suggesting that FOXO3 is a key tumor
suppressor [3,5,8,19].
In addition to phosphorylation, the protein degradation
mechanism plays a key role in regulating FOXO3 tumor
suppressor function. The ubiquitin (Ub)-proteasome pathway is
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such as p53, retinoblastoma, and p27Kip1 proteins in cancer cells
and the E3 Ub-ligases important for the Ub-mediated degradation
of these proteins have been studied [20,21]. Interestingly, the
FOXO3 protein stability is also regulated by the Ub-proteasome
pathway [5,6,19]. However, the E3 Ub-ligases necessary for the
Ub-mediated degradation of FOXO3 and their mechanisms are
not well established. Thus, it is crucial to uncover the E3 Ub
ligases required for FOXO3 protein degradation and elucidate
their molecular mechanisms. Beta-transducin repeat-containing
protein (bTrCP), a novel WD protein [22–26], is a unique E3 Ub-
ligase that plays a major role in substrate recognition in certain
Ub-proteasome pathways [26]. It has been shown that bTrCP1
(also called Fbw1a or FWD1, etc.) ubiquitinates substrates such as
phosphorylated IkB [23] and b-catenin [25] and regulates various
signaling pathways, which are important for tumorigenesis [26].
Here we show that bTrCP1 is a key E3 Ub-ligase that regulates
the protein degradation of FOXO3 tumor suppressor. bTrCP1
interacts with FOXO3 and induces its Ub-dependent degradation
in an IKKb–phosphorylation dependent manner. Using animal
models, we further show that downregulation of FOXO3 protein
level by ectopic expression of bTrCP1 in breast cancer cells
promotes tumor proliferation or tumorigenesis. In contrast,
upregulation of FOXO3 protein level by knocking down the
expression of bTrCP1 in breast cancer cells suppresses their tumor
growth in vivo. These results suggest that bTrCP1 may inhibit
FOXO3 activity through a novel Ub-mediated degradation
mechanism. The important biological and pathological signifi-
cance of this mechanism in the development of cancer is discussed.
Results and Discussion
While we examined the expression of FOXO3 protein in
various cancer cell lines, we unexpectedly found that the level of
FOXO3 protein appeared to be inversely correlated with the level
of bTrCP1 protein in various cancer cell lines (not shown),
suggesting that bTrCP1 E3 Ub-ligase may contribute to a decrease
of FOXO3. Consistently, over-expression of bTrCP1 reduced
FOXO3 protein in 293T cells and this reduction could be reverted
by treating cells with proteasome inhibitors such as MG-132 or
clastro-lactacystin (Figure S1A), suggesting that bTrCP1 may
decrease FOXO3 protein level through proteasomal degradation.
Additionally, over-expression of mutant bTrCP1DF-myc, which
contains a deletion at the N-terminal F-box domain (a.a. 17-52)
that abolishes its E3 ligase activity [26], increased the protein level
of FOXO3 as compared to that in cells cotransfected with the
FOXO3-Flag and bTrCP1-myc in the absence of proteasome
inhibitor MG-132 (Figure S1B), suggesting that the expression of
bTrCP1DF may inhibit the degradation of FOXO3 protein
mediated by endogenous bTrCP1.
To determine if bTrCP1 interacts with endogenous FOXO3 in
vivo, we carried out co-immunoprecipitation (IP) with an antibody
(Ab) against FOXO3 followed by immunoblotting (IB) analysis
with an Ab against bTrCP1 or a reciprocal co-IP with an Ab
against bTrCP1 followed by IB analysis with an anti-FOXO3 Ab.
Indeed, endogenous FOXO3 protein was associated with bTrCP1
protein in vivo (Figure 1A). Using the co-transfection approach, we
further confirmed that HA-FOXO3 protein was specifically
associated with myc-bTrCP1 protein in the transfected cells
(Figure S2A,B).
Because the FOXO3 protein is targeted for proteasomal
degradation after its phosphorylation in mammalian cells [5,6,19],
we sought to determine whether phosphorylation of FOXO3 by
IKKb affects the protein level and ubiquitination (Ub) status of
FOXO3. Indeed, Ub of FOXO3 protein was enhanced significantly
when FOXO3a-myc was co-transfected with HA-Ub and IKKb in
293T cells in the absence of the IKKb inhibitor (Figure 1B). Ub of
FOXO3 was abrogated by a point mutation at Ser-644 (FOXO3-
S644A-myc, whose Ser residue at 644 was mutated to Ala and
resistant to IKKb phosphorylation), suggesting that Ub of FOXO3
requires phosphorylation of FOXO3 at Ser-644 by IKKb.T o
demonstrate the requirement for IKKb activity in the Ub of
FOXO3, we did experiments with the IKKb inhibitor and showed
that inhibition of IKKb activity abrogated the Ub of FOXO3 in
293T cells (Figure 1B), suggesting that the Ub of FOXO3 is
dependent on IKKb activity. As controls, we showed the endogenous
bTrCP1 expression in 293T cells by IB analysis (Figure 1B),
suggesting that endogenous bT r C P 1i ss u f f i c i e n tt of a c i l i t a t eI K K b-
mdeiated the Ub of FOXO3 in 293T cells. In addition, we showed
that the IKKb inhibitor significantly repressed IKKb activity in
phosphorylation of its cellular substrate IkBa n do v e r r o d et h eI K K b-
mediated FOXO3 degradation in the treated cells (Figure S3A-C).
To confirm if over-expression of IKKb induces FOXO3 protein
degradation, we showed that co-transfection of FOXO3 with IKKb
into 293T cells resulted in reduction of the protein level of FOXO3
and this reducing effect could be overridden by treating cells with
various proteasome inhibitors (Figure S2C), suggesting that IKKb
mediates proteasomal degradation of FOXO3 protein.
To determine whether bTrCP1 regulates the Ub status of
FOXO3, we showed that Ub of FOXO3 was enhanced
significantly when FOXO3-myc was co-transfected with HA-Ub
plus bTrCP1 in 293T cells (Figure 1C), suggesting that bTrCP1
promotes Ub of FOXO3 in vivo. As controls, we showed the
endogenous IKKb expression in 293T cells by IB analysis
(Figure 1C), suggesting that endogenous IKKb is sufficient to
facilitate the bTrCP1-induced Ub of FOXO3 in 293T cells. To
demonstrate the requirement for bTrCP1 protein in the Ub of
FOXO3, we did experiments with and without silencing of
bTrCP1 by using bTrCP1-shRNA in the cotransfected 293T cells
and showed that knockdown of bTrCP1 significantly attenuated
the Ub of FOXO3 in these cells (Figure 1D), suggesting that the
Ub of FOXO3 is dependent of bTrCP1 protein.
To titrate in transfected bTrCP1 and IKKb to determine
whether there are synergistic effects of these proteins on FOXO3
Ub, we showed that increasing in transfected bTrCP1 indeed
enhanced the Ub of FOXO3 proportionally in cells cotransfected
both bTrCP1 and IKKb (Figure 1E). Similarly, we demonstrated
that increasing in transfected IKKb augmented the Ub of FOXO3
correspondingly in cells cotransfected both IKKb and bTrCP1
(Figure 1F). These results imply that there may be an additive or
synergistic effect of both proteins (IKKb and bTrCP1) on FOXO3
Ub. However, we do not have definitive evidence to prove that the
observed increase of FOXO3 Ub is due to synergistic effects of
these proteins on FOXO3 Ub.
To show direct Ub of FOXO3 by bTrCP1 E3 Ub-ligase, we
performed the in vitro Ub reactions and showed that bTrCP1
induced Ub of FOXO3 protein in vitro (Figure 1G). Although over-
expression of the mutant bTrCP1DF did not alter its binding to
FOXO3 significantly (Figure S2A,B), Ub and degradation of
FOXO3 protein were abrogated in the reactions using bTrCP1DF
defective in E3 activity (Figure 1H; Figure S1B), suggesting that
Ub-mediated degradation of FOXO3 protein is directly conse-
quential to the E3 activity of bTrCP1.
To confirm that the Ub–mediated FOXO3 protein degradation
is mediated through bTrCP1, we compared the stability of
FOXO3 protein in cells co-transfected with bTrCP1. Over-
expression of bTrCP1 resulted in a rapid decrease in FOXO3
protein level (Figure 2A; Figure S4A), suggesting that bTrCP1
FOXO3, bTrCP1, and IKKb
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that the half-life of FOXO3 is around 4 hours in cells over-
expressing bTrCP1. In addition, silencing bTrCP1 in MCF-7 cells
markedly increased FOXO3 protein (Figure 2B). Furthermore,
mouse embryonic fibroblasts (MEF) lacking bTrCP1 also
augmented the expression of FOXO3 protein (Figure 2C,D),
suggesting that bTrCP1 may be essential for the Ub–mediated
degradation of FOXO3.
As controls, we showed that MCF-7 and MEF cells express
similar levels of IKKb protein (Figure S4B-D). It should be noted
Figure 1. bTrCP1 protein interacts with FOXO3 protein and induces its ubiquitination in vivo and in vitro in an IKKb–phosphorylation
dependent manner. (A) Endogenous proteins in total lysates of MCF-7 cells were subjected to IP with an antibody (Ab) as indicated followed by
immunoblotting (IB) with an anti-bTrCP1 or anti-FOXO3 Ab. A rabbit IgG or an isotype mouse IgG were included as an IP negative control. The input
IB data indicated the integrity of lysates used for IP. (B) 293T cells were cotransfected with HA-ubiquitin (Ub) and FOXO3-Myc or FOXO3-S644A
expression vectors plus IKKb or a control vector (pCDNA3.1) as indicated. At 24 hours after transfection, cells were treated with either DMSO (control)
or the IKKb inhibitor (2 mM) plus the proteasome inhibitor MG-132 (10 mM) for 5 hours. Total lysates were prepared and sonicated extensively for
preventing non-covalent protein-protein associations, and subjected to IP with an anti-myc Ab and followed by IB analysis with an anti-HA Ab. The
typical pattern of HA-tagged Ub was highlighted. The input IB data were performed with Abs against FOXO3, IKKb, phospho-IkBa (p-IkBa), IkBa,
bTrCP1, and b-actin to show the expressions of transfected vectors in cells as indicated, the effect of the IKKb inhibitor (as indicated by the repression
of p-IkBa level), and the integrity of each protein in total lysates used for IP. (C) IP was performed with the lysates of 293T cells that were
cotransfected with the expression vectors as indicated, treated with MG-132 as described above, and followed by IB with an anti-HA Ab. The input IB
data were performed with Abs against myc-tag, FOXO3, bTrCP1, IKKb, and b-actin to show the expressions of transfected vectors in cells and the
integrity of lysates used for IP. (D) Firstly, 293T cells were transfected with either control-shRNA or bTrCP1-shRNA vectors. Twenty four hours post
transfection, these cells were cotransfected with the expression vectors as indicated. Then, at 24 hours after cotransfection, cells were treated with
MG-132 (20 mM) for 4 hours. The total lysates of these 293T cells were prepared and IP was performed as described above and followed by IB with an
anti-HA Ab. The input IB data were performed with Abs against myc-tag, bTrCP1, IKKb, and b-actin as described. (E) 293T cells were cotransfected
with various doses of bTrCP1 expression vector and mutant bTrCP1DF vector and other expression vectors as indicated. IP was performed with the
lysates of these transfected 293T cells, treated with MG-132 as described above, and followed by IB with an anti-HA Ab. The input IB data were
performed with Abs against FOXO3, IKKb, bTrCP1, and b-actin to show the expressions of transfected vectors and endogenous proteins in transfected
cells and the integrity of lysates used for IP. (F) 293T cells were cotransfected with various doses of IKKb expression vector and other expression
vectors as indicated. IP was performed with the lysates of these transfected 293T cells, treated with MG-132, and followed by IB with an anti-HA Ab as
described above. The input IB data were performed with the indicated Abs as described above. (G) In vitro ubiquitination assays. The indicated target
proteins GST-FO(1–300), GST-FO(301–673), and GST (negative control) were incubated with or without E3-ligase protein GST-bTrCP1 in Ub buffer
containing E1, E2 (UbcH5b), Mg-ATP, biotinylated ubiquitin, and IKKb and analyzed by SDS-PAGE and IB with streptavidin conjugated with HRP or an
anti-GST Ab as protein controls (lower panel). (H) The indicated target proteins were incubated with wild-type E3-ligase protein GST-bTrCP1 or
mutant GST-bTrCP1DF in Ub buffer, and analyzed as described above. The positive signals are highlighted with *.
doi:10.1371/journal.pone.0011171.g001
FOXO3, bTrCP1, and IKKb
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bTrCP1 rapidly in 293T cells under normal conditions. Because
the activity of IKKb is usually regulated by certain inflammatory
cytokines such as tumor necrosis factor-a or other oncogenic
factors, it is possible that FOXO3 is not subjected to fast
degradation in the absence of overexpressed bTrCP1 due to the
absence of constitutive phosphorylation of FOXO3 by IKKb
under normal conditions.
Next, we sought to determine whether the bTrCP1–promoted,
IKKb–dependent, degradation of FOXO3 affects its transactiva-
tional activity. Using the reporter co-transfection assays, we
showed that ectopic expression of bTrCP1 resulted in a significant
(,40%) decrease in FOXO3 transactivational activity (Figure 2E).
The mutation of FOXO3 at Ser-644 abrogated the inhibitory
effect of IKKb on the activity of FOXO3 while expression of Akt-
DD resulted in a marked decrease in the activity of FOXO3-
S644A (Figure 2F). In contrast to the wild-type (wt) FOXO3, over-
expression of bTrCP1 could not facilitate the IKKb–mediated
inhibition of mutant FOXO3-S644A.
To elucidate the biochemical mechanism underlying the
bTrCP1-mediated degradation of FOXO3, we examined the
binding between FOXO3 and bTrCP1 by using GST pull-down
assays. We found that bTrCP1 bound FOXO3 mainly at the C-
terminal portion [amino acid (a.a.) 301-673] (Figure 3A). Further
mapping showed that bTrCP1 bound FOXO3 primarily at the C-
terminal domain (a.a. 626–673) and, to a lesser extent, at an
adjacent domain (a.a. 579–625) and a distant domain (a.a. 301–
346) of FOXO3 (Figure 3B; Figure S5A). In addition to the Ser-
644 residue in the C-terminal domain (a.a. 626–673), we identified
a new candidate IKKb phosphorylation motif containing Ser-586
and Ser-590 in the adjacent domain (a.a. 579–625) (Figure S5B).
Using in vitro kinase assays, we showed that these two Ser residues
could be phosphorylated by IKKb whereas mutation of these two
Ser residues to Ala residues abolished phosphorylation by IKKb
(Figure 3C), suggesting that Ser-586 and Ser-590 are indeed new
IKKb phosphorylation sites. Interestingly, mutations of all these
sites (Ser-586, -590, and -644) in the C-terminal domain of
FOXO3-(301–673) GST fusion protein abrogated the interaction
between bTrCP1 and FOXO3-(301–673)AAA (Figure 3D), sug-
gesting that phosphorylation of these sites by IKKb may be crucial
for promoting bTrCP1 binding to FOXO3.
It should be noted that bTrCP1 appears to bind to the 301–346
domain of FOXO3 also. It has been well established that bTrCP1
binds to its substrates through the consensus degron domain
‘‘DSGxxS,’’ where both serines (S) are phosphorylated by kinases
[26]. However, the 301–346 domain of FOXO3 does not contain
such a motif, suggesting that this binding may be independent of
serine phosphorylation and IKKb-mediated phosphorylation.
Although it is interesting that bTrCP1 binds to a site of FOXO3
lacking the degron motif, details of the mechanism underlying the
interaction between bTrCP1 and FOXO3 through a phosphor-
ylation-independent manner remain to be elucidated.
Next, we determined the subcellular localizations of bTrCP1
and FOXO3 proteins and whether endogenous FOXO3 was co-
localized with bTrCP1 in cancer cells. Using fluorescence
microscopy, we showed that bTrCP1 protein is mainly localized
in the nucleus of MCF-7 cells without treatment with any
proteasome inhibitor by using the specific anti-bTrCP1 polyclonal
Ab [22], kindly provided by Klaus Strebel (at NIH). However,
bTrCP1 can be clearly detected in the cytoplasm also (Figure 3E).
Although endogenous FOXO3 protein was located more in the
cytoplasm than nucleus under the same conditions, the majority of
FOXO3 was co-localized with bTrCP1 protein in the cytoplasm
of MCF-7 cells (Figure 3E). In contrast, the treatment with the
IKKb inhibitor, bTrCP1 is predominantly detected in the nucleus
with this anti-bTrCP1 (NIH) Ab and FOXO3 is also primarily
localized in the nucleus (Figure 3F). In addition, we have provided
data showing similar subcellular localization of endogenous
bTrCP1 in BT-549 cells using this specific anti-bTrCP1 Ab
(Figure S6A).
Since it has been shown that bTrCP1 is mainly localized in the
nucleus [22–26], we sought to rule out the possibility that the
observed partial cytoplasmic localization of bTrCP1 may be due
to an antibody artifact. To confirm subcellular localization of
overexpressed bTrCP1-myc (myc tagged) in different cell types, we
transfected MCF-7 and 293T cells with the bTrCP1-myc
expression vector and performed immuno-fluorescence (IF)
analysis with an anti-myc tag Ab and this specific anti-bTrCP1
(NIH) Ab. In agreement with the previous results, our new data
showed that the IF images of both anti-myc and anti-bTrCP1
(NIH) Abs are colocalized mainly in the nucleus but they can be
detected in the cytoplasm, at a relatively lower level, reproducibly
(Figure S6B,C), suggesting that some bTrCP1 may be truly
localized in the cytoplasm under normal conditions. In fact, these
results are consistent with the previously published reports [24,25].
Recently, multiple isoforms of bTrCP1 and bTrCP2 derived
from alternative splicing have been found to display differential
activities in the regulation of Wnt signaling in MCF-7 cells [27],
where bTrCP1-mediated degradation of b-catenin mainly occurs
in the cytoplasm [25]. Interestingly, some isoforms of bTrCP1 are
localized in both cytoplasm and nuclei (i.e., isoforms ‘‘f’’ and ‘‘o’’
[27]). As most anti-bTrCP1 polyclonal Abs cannot distinguish
those isoforms of bTrCP1, it is plausible that some bTrCP1
proteins detected in the cytoplasm by the specific anti-bTrCP1 Ab
may represent certain isoforms such as ‘‘f’’ and ‘‘o’’ of bTrCP1.
In agreement with previous reports [1–3,5,19], phosphoryated
FOXO3 is mainly localized in the cytoplasm. Using IF analysis,
we further confirm that serine (Ser) residues of FOXO3 proteins
were phosphoryated in 293T and MCF-7 cells cotransfected with
FOXO3-HA (or FOXO3-myc) plus IKKb vectors and primarily
Figure 2. bTrCP1 induces degradation of FOXO3 protein and inhibits its transactivating activity. (A) The stability of FOXO3 protein was
assayed by cycloheximide (CHX) chase in 293T cells co-transfected with FOXO3-myc and bTrCP1 or a control vector (pCDNA3.1). Lysates of the
transfected cells were prepared at 2, 4, 6, 8 hour (h) and 0 h (control) after addition of CHX, and subjected to immunoblotting (IB) with an anti-myc
Ab. Graph shows results of densitometric analysis of 3 CHX chase experiments (mean 6 SD) using 0 h (control) as 100%. (B) MCF-7 cells were
transfected with small interfering RNA (siRNA) targeting bTrCP1 or control-siRNA (control). Total lysates of the transfected cells were subjected to IB
analysis with an Ab against bTrCP1 or FOXO3 or b-actin (loading control) as indicated. (C) Total lysates of wild-type (Wt) and bTrCP1(–/–) MEF cells
were subjected to IB analysis with an Ab against FOXO3 or bTrCP1 or b-actin (loading control). (D) bTrCP1(–/–) and bTrCP1(+/+) MEF cells were fixed,
and the expression and subcellular localization of endogenous FOXO3 was detected using an anti-FOXO3 Ab and followed by an Alexa Fluor 546
(red) -conjugated secondary Ab, and analyzed with fluorescence microscopy. A fluorescent dye 49-6-Diamidino-2-phenylindole (DAPI) was used to
visualize the nuclei. An average of ,200 cells stained with anti-FOXO3 Ab were analyzed and a histogram shows the relative FOXO3 expression level
in MEF cells. (E and F) Total lysates of 293T cells cotransfected with FRE-luc (firefly luciferase (luc) reporter containing FOXO-responsive elements),
pRL-TK (renilla luc as a transfection control for normalization), bTrCP1, FOXO3 (A) or FOXO3-S644A (FO-S644A) (B), plus IKKb or Akt-DD (an active Akt)
as indicated and subjected to luc assays.
doi:10.1371/journal.pone.0011171.g002
FOXO3, bTrCP1, and IKKb
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FOXO3-S644A protein was predominantly localized in the
nucleus even in cells overexpressed IKKb (Figure S8A). As
controls, we showed that mutant FOXO3-S644A protein was also
primarily localized in the nucleus in cells without IKKb
overexpression (Figure S8B). In contrast, we showed that wt
FOXO3-HA protein was primarily colocalized with IKKb in the
cytoplasm of cells overexpressed IKKb (Figure S8C) while wt
FOXO3-HA could be detected in the cytoplasm and nucleus
without IKKb overexpression (Figure S8D).
As cells express a homolog of bTrCP1 (bTrCP2), we examined
if bTrCP2 protein could interact with FOXO3 protein in vitro and
in vivo. Using GST pull-down assays, we showed that bTrCP2
protein could not bind to FOXO3 protein directly in vitro (Figure
S9A). Using IF analysis, we showed that bTrCP2 protein could be
detected in both the cytoplasm and nucleus while FOXO3 protein
was primarily located in the cytoplasm (Figure S9B). Although it
appears that bTrCP2 may be localized somewhat more in the
nucleus than cytoplasm, it is possible that some isoforms of
bTrCP2 [27], as described above, are located more in the nucleus
than cytoplasm. Thus, it is probable that FOXO3 protein may not
be co-localized with bTrCP2 in cells under normal conditions
(Figure S9B). Collectively, these data suggest that the Ub–
mediated FOXO3 protein degradation is mainly mediated
through bTrCP1 but may not be regulated by bTrCP2. These
results further suggest that cells in which bTrCP1 is silenced alone
and bTrCP1(2/2) MEFs express high levels of FOXO3 protein.
Moreover, we determined if this increase of FOXO3 protein by
silencing bTrCP1 would affect cell survival or death after DNA
damage. We showed that exposure of bTrCP1(–/–) MEF cells to
camptothecin (CPT), a topoisomerase I inhibitor, for 48 hours led
to cellular apoptosis, whereas wt MEFs did not have significant
apoptosis (Figure 4A,B). As described above, silencing bTrCP1
increased FOXO3 protein significantly (Figure 2B–D), suggesting
that the observed pro-apoptotic phenotype in cells lacking
bTrCP1 may be mediated via FOXO3 increase. To further
confirm that the apoptotic effect from silencing bTrCP1 was
mediated via FOXO3, we showed that silencing both FOXO3
and bTrCP1 together (double knockdown) in BT549 cells
abrogated the effect of apoptosis induced by bTrCP1 single
Figure 3. FOXO3 protein is associated and co-localized with bTrCP1 protein and inhibition of IKKb abolishes co-localization of
FOXO3 with bTrCP1 in cells. (A) GST-pull down in vitro assays. Whole lysates from 293T cells overexpression of IKKb were incubated with the GST-
FOXO3 [GST-FO (1–300) and GST-FO (301–673)] fusion proteins as indicated and GST alone (negative control), and analyzed by SDS-PAGE and
immunoblotting (IB) with an anti-bTrCP1 Ab (upper panel) and an anti-GST Ab as protein controls (lower panel). (B) The same lysates were incubated
with the eight GST-FO sequential fusion fragments spanning the entire carboxy (C)-terminal region of FOXO3 (301–673) as indicated and GST, and
analyzed as described. (C) In vitro kinase assays. Lysates of 293T transfected with HA-IKKb were IP with an anti-HA, and kinase assays were performed
with fusion proteins GST-FO (579–625) and GST-FO (579–625)-AA, whose Ser-586 and Ser-590 residues were mutated to Ala (A) residues, and GST
protein (negative control). (D) Lysates from 293T cells were incubated with fusion proteins GST-FO (301–673) and GST-FO (301–673)AAA, whose Ser-
586, Ser-590, and Ser-644 residues were mutated to Ala residues in the C-terminal domain of FOXO3, and GST protein, and analyzed by IB with an
anti-bTrCP1 Ab (upper panel) and an anti-GST Ab (lower panel). The significant signal is indicated with *. (E) MCF-7 cells were treated with DMSO
(control vehicle for the IKKb inhibitor shown in F below) or untreated, fixed, and the subcellular localizations and co-localization of endogenous
FOXO3 and bTrCP1 proteins were detected using an anti-FOXO3 and a specific anti-bTrCP1 Ab (obtained from K. Strebel at NIH) [22] and followed by
an Alexa Fluor 594- or 488-conjugated secondary Ab, respectively, and fluorescence microscopy. DAPI was used to show the nuclei, and co-
localization of FOXO3 with bTrCP1 was shown as the merged images (yellow). These results are the same as those untreated cells. (F) MCF-7 cells
were treated with the IKKb inhibitor (2 mM), fixed, and the subcellular localizations and co-localization of endogenous FOXO3 and bTrCP1 proteins
were detected using Abs against FOXO3 and bTrCP1 (NIH) as described above and followed by an Alexa Fluor 594- or 488-conjugated secondary Ab,
respectively, and fluorescence microscopy. DAPI was used to show the nuclei, and no co-localization (the merged yellow images) between nuclear
FOXO3 and cytoplasmic bTrCP1 was detected.
doi:10.1371/journal.pone.0011171.g003
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PLoS ONE | www.plosone.org 6 July 2010 | Volume 5 | Issue 7 | e11171Figure 4. DNA damage induces apoptosis in cells lacking bTrCP1 that can be reverted by silencing FOXO3 and ectopic expression
of bTrCP1 promotes tumor growth whereas silencing bTrCP1 in cancer cells suppresses tumorigenesis in vivo. (A) DNA samples
extracted from Wt MEF or bTrCP1(–/–) MEF cells treated with camptothecin (CPT) (20 mM) for 24 or 48 h or control (DMSO) were subjected to DNA
fragmentation assay. Equal amounts of the extracted DNA (2 mg/lane) and size markers (M) were subjected to electrophoresis on 2% agarose gels,
which were stained with ethidium bromide and photographed. (B) MEF cells treated with CPT (20 mM) or DMSO (control) (0 h) for 48 h were stained
with propidium iodide (PI), and the cell-cycle profiles were determined by flow cytometry. The changes in percentage of cell-cycle statuses between
CPT treatment and control were shown in a histogram. (C) BT549 cells were transfected with bTrCP1-siRNA (si-bTrCP1) or control RNA (si-control).
DNA fragmentation assay was performed as described above. (D) BT549 cells were transfected with control RNA (si-control) alone or transfected with
FOXO3-siRNA (si-FOXO3) plus bTrCP1-siRNA (si-bTrCP1). DNA fragmentation assay was performed. (E) The 231 cells were transfected with bTrCP1-
siRNA (designated 231-bTrCP-kd) or transfected with a bTrCP1 expression vector (designated 231-bTrCP-ov). These transfected cells or 231 control
cells were injected into the nude mice as described. *, P,0.05 between 231 control versus 231-bTrCP-kd or 231-bTrCP-ov. (F) At 28 days after tumor
cell implantation, breast tumors derived from the nude mice bearing 231 (control) or 231-bTrCP-ov or -bTrCP-kd tumors were resected, fixed,
sectioned, and placed on slides. Tumor specimens were subjected to immuno-histochemical staining with an Ab specific to bTrCP1 or FOXO3. Slides
were examined at 406magnification with a microscope and representative fields are shown. Scale bars indicate 50 mm. (G) Total lysates prepared
from 231-bTrCP-ov and 231-bTrCP-kd breast tumor specimens were subjected to IB analysis with Abs against FOXO3, bTrCP1, and b-actin (loading
control). (H) A diagram depicts the role of bTrCP1 in promoting tumorigenesis through inducing degradation of FOXO3 protein. The subcellular
localization of FOXO3 is shown to denote FOXO3 activity.
doi:10.1371/journal.pone.0011171.g004
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the effect of silencing bTrCP1 on the observed apoptosis increase
is mediated through FOXO3.
We sought to determine whether silencing endogenous bTrCP1
expression could augment FOXO3 protein level and lead to tumor
suppression in vivo and whether ectopic expression of bTrCP1
could reduce FOXO3 protein level and promote tumor growth in
an orthotopic breast tumor mouse model. When the MDA-MB-
231 (abbreviated as 231) cells with bTrCP1-knockdown (231-
bTrCP-kd) or 231 control cells were injected into the mammary
fat pads of female athymic nude mice, the tumor growth of 231-
bTrCP-kd was strongly suppressed as compared to that of 231
control cells (Figure 4E). This tumor suppression phenotype is
presumably caused by elevation of FOXO3 that promotes
apoptosis. In contrast, when the cells over-expressing bTrCP1
(231-bTrCP-ov) were injected into nude mice in the same fashion,
the growth rate of 231-bTrCP-ov cells was enhanced as compared
to that of 231 control cells (Figure 4E). This growth increase is
presumably induced by the bTrCP1-mediated FOXO3 degrada-
tion as described above. Using immunohistochemical staining and
IB analysis, we confirmed that the level of FOXO3 was indeed
inversely correlated with the expression level of bTrCP1 in the
xenograft tumor samples (Figure 4F,G). Because 231 cells are
tumorigenic in nude mice and the level of endogenous FOXO3 in
231 cells is low, over-expression of bTrCP1 in 231 cells (231-
bTrCP-ov) could only further reduce FOXO3 protein level
slightly. Therefore, the tumor growth rate of 231-bTrCP-ov cells
in mice could be enhanced only partially as compared to that of
231 control cells (Figure 4E).
We have demonstrated a novel mechanism underlying the Ub-
mediated degradation of FOXO3 protein in tumorigenesis. Our
findings indicate that bTrCP1 interacts with FOXO3, resulting in
promoting Ub-mediated degradation of FOXO3 protein that
contributes to tumor growth. This is the first time that bTrCP1 is
shown to regulate FOXO3 protein degradation and its tumor
suppressor function. Based on these findings, we propose a model
for a unique role of bTrCP1 in regulating FOXO3 protein
degradation and promoting tumorigenesis (Figure 4H). These
findings suggest that cancer cells may acquire sustained resistance
to FOXO3-mediated apoptosis through a regulated degradation
of FOXO3 protein by bTrCP1 oncogenic E3-ligase. Evidence is
emerging to indicate that certain key substrates are targeted by the
E3 ligases in the Ub-mediated protein regulation [28]. In addition
to FOXO3, it is intriguing that bTrCP1 has been found to interact
with another key tumor suppressor p53 [29] and promote its Ub-
dependent degradation, resulting in tumorigenesis. Our findings
that a unique oncogenic bTrCP1 E3-ligase mediates augmented
degradation of FOXO3 protein will significantly contribute to an
understanding of the control of FOXO3 protein stability and
extend the parallel mechanism of regulation between FOXO3 and
p53 in cancer cells. Moreover, this dual inhibition of FOXO3 and
p53 tumor suppressor function by bTrCP1 suggests that
compounds inhibiting bTrCP1 protein may be innovative
therapeutic modalities for suppression of tumor growth and the
development of cancer.
Materials and Methods
Ethics Statement
All experiments involving mice were approved by the
institutional review boards of Stanford University and Albert
Einstein College of Medicine. All research involving animals were
conducted according to the guidelines of Institutional Animal Care
and Use Committees of Stanford University and Albert Einstein
College of Medicine. The injected mice were housed in groups,
which were provided with food and sterile water. When bedding
was contaminated, the mice were transferred into clean cage first
and the contaminated bedding was discarded according to
Institutional guidelines. There was no change after the appearance
of tumors and no nesting material was provided for these mice.
The mice were checked daily including weekend.
Antibodies and reagents
Antibodies (Abs) specific to FOXO3 (FKHRL1, H-144; and N-
16), IKKb, p-IkBa,I kBa, and bTrCP2 were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). A specific anti-
FOXO3 Ab was obtained from Imgenex Corp. Abs against b-
tubulin, b-actin, hemagglutinin (HA), myc-tag and Flag-tag were
purchased from Sigma. An anti-bTrCP1 was obtained from
Zymed Laboratories, Inc. (San Francisco, CA). An anti-p27Kip1
Ab was purchased from BD PharMingen (San Diego, CA). Abs
against myc-tag (9E10) and poly-ADP-ribose polymerase (PARP)
was purchased from Roche Applied Science (Indianapolis, IN),
respectively. Additional anti-myc-tag Abs were purchased from
Abcam Inc. (Cambridge, MA) and GenScript USA Inc. (Piscat-
away, NJ). The specific anti-bTrCP1 polyclonal Abs [22] were
obtained from K. Strebel (at NIH). Alexa 488 (green)- and Alexa
546 or 555 or 594 or 647 (red)-conjugated secondary Abs and
Texas red- and FITC-conjugated secondary Abs were obtained
from Molecular Probes (Eugene, OR), Invitrogen Corp. An anti-
phosphoserine (p-Ser) Ab was purchased from Invitrogen.
Camptothecin (CPT) and the proteasome inhibitors such as
MG-132, clastro-Lactacystin (c-Lactacystin), MG-101 (also named
ALLN or LLNL), and cycloheximide were purchased from Sigma
(St. Louis, MO) or Calbiochem (CA), dissolved in DMSO or
ethanol and stored in aliquots at 280uC.
Cell culture and cell lines
All cell lines were grown under normal conditions at 37uC and
5% CO2 in DMEM/F12 supplemented with L-glutamine,
penicilline/streptomycin and 10% fetal bovine serum (FBS). The
tumor type origins of the cell lines are: MDA-MB-231 and MCF-
7, human breast epithelial adenocarcinoma; BT474 and BT549,
human breast epithelial ductal carcinoma; 293T, human kidney
epithelial cell line expressing SV40 large T antigen. Mouse
embryonic fibroblasts (MEF) bTrCP1(–/–) and their control wt
MEF cells have been described previously [30].
Immunoprecipitation (IP) and immunoblotting (IB)
All IP experiments were performed as described previously [17].
Briefly, cells were washed twice with PBS and lysed with lysis
buffer containing protease inhibitors at 4uC for 20 min. Total
lysates were sonicated extensively for preventing non-specific
protein-protein associations. For Ub analysis, the lysates were
prepared with lysis buffer under denaturing conditions and
sonicated extensively to prevent non-covalent protein-protein
associations. Protein samples were first precleared with a
nonspecific IgG antibody. Precleared lysates were then incubated
with an Ab by rotating at 4uC overnight followed by the addition
of 25 ml of 50% protein A- or Protein G-sepharose slurry and
rotating for 1 hour. Protein A/G beads were collected and washed
with lysis buffer four times. Immunoprecipitates were resolved by
6% or 10% or 12% SDS-polyacrylamide gel eletrophoresis
(PAGE) and analyzed by IB analysis. After washing, immunopre-
cipitates were resolved by SDS-PAGE and analyzed by IB
analysis. For IB analysis, the protein samples were subjected to
SDS-PAGE and transferred onto nitrocellulose or polyvinylidene
difluoride (PVDF) membranes. The membranes were blocked
FOXO3, bTrCP1, and IKKb
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20 and incubated with primary Abs and then with horseradish
peroxidase-conjugated secondary Abs according to the manufac-
turer’s instructions. IB analysis was visualized by an enhanced
chemiluminescence (ECL) kit obtained from Pharmacia or Santa
Cruz Biotechnology.
In vitro ubiquitination assays
E3-ligase proteins (GST-bTrCP1 and GST-bTrCP1DF) and
target proteins (GST (negative control), GST-FO(1–300), and
GST-FO(301-673)) were produced as GST-fusion proteins from E.
coli and purified. In vitro ubiquitination assays were carried out
using in vitro ubiquitination assay kit (BIOMOL). In vitro
ubiquitination assays were carried out in 50 ml of ubiquitinylation
buffer, containing E1 (100 nM), E2 (UbcH5b, 2.5 mM), Mg-ATP
(5 mM), E3 (0.1 mM), target protein (1 mM), inorganic pyrophos-
phatase solution (100 U/ml), DTT (5 mM), Mg-ATP (25 nM),
biotinylated ubiquitin (2.5 mM), and the cell extracts (5 mg protein)
from 293T cells over-expression of IKKb. The reaction mixtures
were incubated for 2 hours at 37uC and then terminated with 2X
nonreducing gel loading buffer. The protein samples were
subjected to SDS-PAGE (8% gel) and transferred onto nitrocel-
lulose membrane. The membranes were incubated with strepta-
vidin-HRP solution (Vectastain ABC Elite kit) for 1 hour, washed
with BSA/TBST (Tris-buffered saline containing 0.05% Tween
20) solution for 1 hour and visualized by chemiluminescence.
Immunofluorescence (IF)
MEF bTrCP1(–/–) and bTrCP1(+/+) cells were seeded onto
sterile glass coverslips, which were placed in a 12-well culture
plate. Cells were fixed with 4% paraformaldehyde for 10 min at
room temperature before being permeabilized in 0.5% Triton X-
100. Slide culture chambers were washed with PBS and blocked
with PBS containing 2% BSA, incubated with an Ab specific to
FOXO3 or bTrCP1 (1:100 to 1:500 dilution), followed by Alexa
546 or 555 or 594 or 647 (red)-conjugated anti-rabbit and Alexa
488 (green)-conjugated anti-mouse secondary Abs (Molecular
Probes, Eugene, OR). Cells were counterstained with DAPI
(Molecular Probes, Eugene, OR) to show the nuclei. Specific
staining was visualized and images were captured with a Leica SP2
AOBS confocal laser scanning microscope or an Olympus IX81
system confocal microscope as described previously [17].
siRNA transfection
MCF-7 or 293T cells were transfected with specific small-
interfering RNA (siRNA) targeting FOXO3 (si-FOXO3a) (59-
GAGCUCUUGGUGGAUCAUCdTdT-39)o rbTrCP1 (bTrCP1
siRNA duplexes were obtained from Dharmacon) or control luc
siRNA (59-CUUACGCUGAGUACUUCGAdTdT-39) duplex
(Dharmacon) (4 uM/2610
6 cells) by electroporation using Nu-
cleofector 1 (amaxa) or Lipofectamine 2000 (Invitrogen Corp.) as
described previously [17]. The control vector (without shRNA),
the scrambled shRNA control vector, and the bTrCP1-shRNAs
vectors were purchased from OriGene Technologies, Inc. (Rock-
ville, MD).
DNA fragmentation Assay
DNA fragmentation in apoptotic cells was determined by the
standard gel electrophoresis. Cells were treated with the indicated
drugs or control for 24 or 48 hours, harvested, washed with PBS,
and incubated with lysis buffer on ice for 20 min. Samples were
then centrifuged at 4uC at 12,0006g for 30 min. DNA was
extracted with phenol/chloroform and precipitated with ethanol.
The DNA pellet was then washed with 70% ethanol, dissolved in
water containing RNase, and incubated at 37uC for 30 minutes.
The extracted DNA (2 mg/lane) was subjected to electrophoresis
on 2% agarose gels, stained with ethidium bromide, and then
photographed.
Cell cycle analysis
Wild type (Wt) and bTrCP1(–/–) MEF cells were treated with
CPT (20 mM) or control (DMSO) for 5 hours. Cells were rinsed
with PBS and fixed in 70% ethanol at 4uC overnight. The fixed
cells were then washed twice with PBS and resuspended in PBS
containing 10 mg/ml PI (Roche Applied Science) and 10 mg/ml
RNase A (Sigma), and incubated for 1 hour at room temperature
before analysis. The samples were analyzed by flow cytometry as
described previously [17]. Cell populations in different phases of
cell cycle were determined.
GST pull-down assays
For GST pull-down assays: the various GST-fusion FOXO3
plasmids containing the specific domains of FOXO3 (GST-FO-
(1–301), (301–673), (301–346), (347–392), (393–439), (440–485),
(486–531), (532–578), (579–625), and (626–673)) were prepared.
The various GST-fusion FOXO3 expression vectors were
constructed as described previously [17]. Briefly, the GST-FO
fusion proteins and GST proteins (control) were expressed in
Escherichia coli BL21 (Invitrogen, Carlsbad, CA) lysed in a GST
lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton X-
100, and protease inhibitors), and immobilized onto glutathione-
Sepharose beads (Pharmacia Biotech). Total lysate (1 mg) from
293T cells that were transfected with IKKb or treated with TNFa
(10 ng/ml) in binding buffer (50 mM Tris, pH 7.5, 100 mM
NaCl, 10 mM MgCl2, 0.5% Nonidet P-40 and protease
inhibitors) was mixed with the GST-FO or GST (control)
containing glutathione-Sepharose beads. The protein complex
formation on glutathione-Sepharose beads was carried out
overnight at room temperature or 4uC with shaking. The beads
were washed with binding buffer, and the bound protein
complexes were disrupted and proteins were denatured directly
by boiling in SDS loading buffer.
Immunohistochemical staining and statistical analysis
Immunohistochemical staining was performed as described
previously [17]. Breast tumors were excised from the tumor-
bearing mice 28 days (231-control, 231-bTrCP-ov, and 231-
bTrCP-kd tumors) after inoculation of the test or control cells. Five
independent tumors (each from a different mouse) were taken
from each test group for testing. Tumor samples were fixed in
formalin, sectioned, placed on slides, and incubated with specific
Abs. Sections were then treated with biotin-conjugated secondary
Ab followed by avidin biotin-peroxidase complex and amino-ethyl
carbazole as a chromogen. All data are expressed as means and
standard deviations (SD) from at least three determinations. The
statistical significance of differences in cell proliferation and tumor
growth between two groups was analyzed with two-sided unpaired
Student’s t tests when the variances were equal, or with Welch’s
corrected t tests when the variances were unequal, with Graphpad
statistical software (San Diego, CA). All statistical tests were two-
sided, and P values less than 0.05 were considered statistically
significant.
Animal studies
To determine tumorigenicity and establish orthotopic breast
cancer animal models, female athymic (nu/nu) nude mice were
FOXO3, bTrCP1, and IKKb
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(Frederick, MD) or NCR NU-M-F (Taconic Farm) and main-
tained aseptically in an athymic animal room. For tumor-cell
implantation, cells (derivatives of MDA-MB-231 (231-control,
231-bTrCP1-ov, and 231-bTrCP1-kd)) in log-phase growth were
harvested, washed with phosphate buffered saline (PBS), and
resuspended in PBS. Then cells (2610
6 in 0.1 ml PBS) were
injected into the mammary fat pad of each mouse. The tumor sizes
were measured twice per week with a Vernier caliper. Data are
presented as means and standard deviations of two experiments
with 5 mice in each group. All procedures were performed in
compliance with guidelines of Institutional Animal Care and Use
Committee.
Supporting Information
Figure S1 Ectopic expression of bTrCP1 decreases FOXO3
protein level that can be reverted by treating cells with proteasome
inhibitors. (A) Total lysates from 293T cells that were cotrans-
fected with FOXO3-Flag plus bTrCP1, treated with the protea-
some inhibitor MG-132 or clastro-Lactacystin (c-Lactacystin) or
DMSO (vehicle control), were analyzed by immunoblotting (IB)
with an indicated antibody (Ab). b-actin was used to show the
protein loading control. (B) The effect of overexpression of wild-
type (wt) and mutant bTrCP1 on the levels of FOXO3 protein.
Total lysates of 293T cells that were cotransfected with a control
vector (pcDNA3.1) or FOXO3-Flag alone or FOXO3-Flag plus
wt bTrCP1-myc or the mutant bTrCP1DF-myc (E3 mutant)
vector as denoted, treated with MG-132 or DMSO, and
untransfected 293T cells (negative control, the far left lane), were
analyzed by IB analysis with an indicated Ab as described above.
The molecular weights (kDa) of proteins are highlighted.
Found at: doi:10.1371/journal.pone.0011171.s001 (3.00 MB TIF)
Figure S2 bTrCP1 is associated with FOXO3 in cells over-
expressing these proteins in vivo. (A) Total lysates of 293T cells
cotransfected with hemagglutinin (HA)-tagged FOXO3 plus a
myc-tagged bTrCP1 or mutant bTrCP1DF, and IKKb or an
empty vector were analyzed by immuno-precipitation (IP) with an
anti-myc tag antibody (Ab) followed by immunoblotting (IB) with
an anti-HA Ab. (B) The same lysates as described in A were
subjected to reciprocal IP with an anti-HA followed by IB with an
anti-myc Ab. IB analysis for FOXO3 or myc-bTrCP or b-actin
with the indicated Ab was shown as a control of protein input
before IP. (C) Total lysates of 293T cells cotransfected with
FOXO3-Flag and IKKb, treated with c-Lactacystin or MG-101
(also named ALLN or LLNL) or DMSO, were analyzed by IB
with an anti-Flag or anti-b-actin Ab (loading control).
Found at: doi:10.1371/journal.pone.0011171.s002 (0.15 MB TIF)
Figure S3 The IKKb inhibitor significantly represses IKKb
activity and overrides the IKKb-mediated FOXO3 degradation;
bTrCP1-shRNAs significantly reduce bTrCP1 expression in
transfected cells. (A, B) 293T cells were treated with an equal
amount of DMSO (control vehicle) (A) or IKKb inhibitor (B)
under normal cell culture conditions. Four hours after treatment,
cells were washed, fixed, and stained with antibodies (Abs) against
IKKb and phospho-IkB (p-IkB) and followed by the Alexa Fluor
488 (green)- and Alexa Fluor 647 (red)-conjugated secondary Abs,
respectively, and fluorescence microscopy. A nuclear stain 49,6-
diamidino-2-phenylindole (DAPI) was used to show the nuclei.
Co-localizations between IKKb and p-IkB images are shown as
the merged yellow/orange images. (C) Total lysates from 293T
cells that were transfected with either IKKbvector or pcDNA3.1
(control) vector, treated with the IKKb inhibitor or DMSO
(control) as indicated, were analyzed by immunoblotting (IB) with
an Ab against FOXO3 or IKKb or p-IkBa or b-actin (as protein
loading control). The molecular weights of proteins are highlight-
ed. (D) Over-expression of bTrCP1-shRNAs slienced endogenous
bTrCP1 expression in the transfected cells. 293T cells were co-
transfected with the control vector (without shRNA) or the
scrambled shRNA control vector or the bTrCP1-shRNAs vectors.
At 48 hours post transfection, total lysates were prepared from the
transfected cells and subjected to IB analysis with an Ab against
bTrCP1 or b-actin (loading control) as described above.
Found at: doi:10.1371/journal.pone.0011171.s003 (0.72 MB TIF)
Figure S4 Ectopic expression of bTrCP1 increases FOXO3
protein degradation; the test cell lines express similar levels of
endogenous IKKb protein. (A) The 293T cells were cotransfected
with FOXO3-myc plus bTrCP1-myc and IKKb and followed by
cycloheximide (CHX) chase (100 mg/ml) at 2, 4, 6, and 8 hour.
Total lysates of these cells were analyzed by IB with an anti-myc
(detecting FOXO3-myc 100-kDa protein and bTrCP1-myc 70-
kDa protein expression control) or anti-b-actin antibody (Ab)
(loading control). (B-D) MCF-7 cells (B), mouse embryonic
fibroblasts (MEF) bTrCP1(+/+) cells (C), and MEF bTrCP1
(2/2) cells (D) were washed, fixed, and stained with an Ab against
IKKb and followed by the Alexa Fluor 488 (green)-conjugated
secondary Ab, and fluorescence microscopy. A nuclear stain 49,6-
diamidino-2-phenylindole (DAPI) was used to show the nuclei.
Found at: doi:10.1371/journal.pone.0011171.s004 (3.00 MB TIF)
Figure S5 The candidate protein domains and sequence motifs
involved in the interaction between FOXO3 and bTrCP1. (A) A
diagram depicts the relative positions of GST-FOXO3 (GST-FO)
fusion proteins in the entire carboxy-terminal region of FOXO3
(301–673). The orange color highlights a candidate domain in the
GST-FO(579–625) or GST-FO(626–673) fragment that interacts
with bTrCP1 significantly in the GST-pull down assays. (B) The
putative IKKb consensus sequences for phosphorylation (S, serine;
T, threonine; and X, any amino acid) in the FOXO3 (579–625)
domain are shown, and the new candidate S residues that are
phosphoryated by IKKb are highlighted by boxes in red dots.
Found at: doi:10.1371/journal.pone.0011171.s005 (3.00 MB TIF)
Figure S6 Subcellular localization of bTrCP1 protein in
different cell types. (A) BT-549 breast cancer cells were treated
with DMSO, fixed, and the subcellular localizations and co-
localization of endogenous FOXO3 and bTrCP1 proteins were
detected using antibodies (Abs) against FOXO3 and bTrCP1 and
followed by an Alexa Fluor 555- or 488-conjugated secondary
Abs, respectively, and fluorescence microscopy. DAPI was used to
show the nuclei, and co-localizations of FOXO3 with bTrCP1
images are shown as the merged yellow/orange images. (B, C)
Overexpression of bTrCP1-myc in MCF-7 cells (B) and 293T cells
(C) confirms the subcellular localizations of bTrCP1-myc. At
48 hours after transfection, cells were fixed and stained with Abs
against myc-tag or bTrCP1, a specific Ab that was developed by
K. Strebel at NIH as described previously [22], and followed by an
Alexa Fluor 647- or 488-conjugated secondary Abs, respectively,
and fluorescence microscopy as described above.
Found at: doi:10.1371/journal.pone.0011171.s006 (3.00 MB TIF)
Figure S7 The phosphorylation status of FOXO3 protein in
cells over-expressing FOXO3 and IKKb. (A, B) 293T cells were
co-transfected with FOXO3-HA vector plus control (A) or IKKb-
Flag (B) vector. Forty-eight hours after transfection, cells were
washed, fixed, and stained with antibodies against HA-tag and
phosphoserine (p-Ser) and followed by the Alexa Fluor 647 (red)-
and Alexa Fluor 488 (green)-conjugated secondary antibodies,
FOXO3, bTrCP1, and IKKb
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the nuclei. Co-localizations between FOXO3-HA and p-Ser
images are shown as the merged yellow/orange images. (C, D)
MCF-7 cells were co-transfected with FOXO3-myc vector plus
control (C) or IKKb-Flag (D) vector. Forty-eight hours after
transfection, cells were stained with antibodies against myc-tag and
p-Ser and followed by secondary antibodies and fluorescence
microscopy as described above. Co-localizations between
FOXO3-myc and p-Ser images are shown as described.
Found at: doi:10.1371/journal.pone.0011171.s007 (3.00 MB TIF)
Figure S8 The subcellular localization of mutant FOXO3-
S644A protein in cells overexpressed FOXO3-S644A and IKKb.
(A, B) 293T cells were co-transfected with mutant FOXO3-
S644A-myc plus IKKb-Flag (A) vectors or FOXO3-S644A-myc
alone (B). Forty-eight hours after transfection, cells were washed,
fixed, and stained with antibodies (Abs) against myc-tag and Flag-
tag and followed by the Alexa Fluor 546 (red)- and Alexa Fluor
488 (green)-conjugated secondary Abs, respectively, and fluores-
cence microscopy. DAPI was used to show the nuclei. (C, D)
MCF-7 cells were co-transfected with wild-type FOXO3-HA plus
IKKb-Flag vectors (C) or FOXO3-HA alone (D). At 48 hours post
transfection, cells were fixed and stained with Abs against myc-tag
and Flag-tag and followed by secondary Abs and fluorescence
microscopy as described above. Co-localizations between
FOXO3-HA and IKKb-Flag images are shown as the merged
yellow/orange images.
Found at: doi:10.1371/journal.pone.0011171.s008 (3.00 MB TIF)
Figure S9 bTrCP2 does not bind FOXO3 protein significantly
in vitro and in vivo. (A) GST-pull down in vitro assays. Whole lysates
from 293T cells overexpression of IKKb were incubated with the
GST-FOXO3 [GST-FO (1–300) and GST-FO (301–673)] fusion
proteins as indicated and GST alone (negative control), and
analyzed by SDS-PAGE and immunoblotting with an anti-
bTrCP2 antibody (Ab) (upper panel) and an anti-GST Ab (lower
panel) as protein controls. (B) Co-localization between endogenous
bTrCP2 and FOXO3 in HeLa cells. Cells cultured under normal
conditions were stained with Abs against FOXO3 and bTrCP2
and followed by an Alexa Fluor 594 (red)- and Alexa Fluor 488
(green)-conjugated secondary Abs, respectively, and fluorescence
microscopy. DAPI was used to show the nuclei. No significant co-
localization (the merged yellow images) between endogenous
FOXO3 with bTrCP2 was detected.
Found at: doi:10.1371/journal.pone.0011171.s009 (3.00 MB TIF)
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